NEW YORK--(BUSINESS WIRE)--Pluristem Therapeutics Inc. (NASDAQ:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company signed an agreement with KKS, retaining them as the Contract Research Organization (CRO) for its upcoming Critical Limb Ischemia (CLI) multi center clinical trial utilizing Pluristem’s placental-derived adherent stromal cell product, PLX-PAD.
